Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma
- Kimberly J. Bussey†1, 2Email authorView ORCID ID profile,
- Aditi Bapat†2,
- Claire Linnehan2,
- Melissa Wandoloski2,
- Erica Dastrup2,
- Erik Rogers2,
- Paul Gonzales3 and
- Michael J. Demeure2
© Bussey et al. 2016
Received: 25 September 2015
Accepted: 15 December 2015
Published: 11 January 2016
Adrenocortical carcinoma (ACC) is an aggressive cancer with a 5 year survival rate of 20–30 %. Various factors have been implicated in the pathogenesis of ACC including dysregulation of the G2/M transition and aberrant activity of p53 and MDM2. Polo-like kinase 1 (PLK-1) negatively modulates p53 functioning, promotes MDM2 activity through its phosphorylation, and is involved in the G2/M transition. Gene expression profiling of 44 ACC samples showed that increased expression of PLK-1 in 29 % of ACC. Consequently, we examined PLK-1’s role in the modulation of the p53 signaling pathway in adrenocortical cancer.
We used siRNA knock down PLK-1 and pharmacological inhibition of PLK-1 and MDM2 ACC cell lines SW-13 and H295R. We examined viability, protein expression, p53 transactivation, and induction of apoptosis.
Knocking down expression of PLK-1 with siRNA or inhibition of PLK-1 by a small molecule inhibitor, BI-2536, resulted in a loss of viability of up to 70 % in the ACC cell lines H295R and SW-13. In xenograft models, BI-2536 demonstrated marked inhibition of growth of SW-13 with less inhibition of H295R. BI-2536 treatment resulted in a decrease in mutant p53 protein in SW-13 cells but had no effect on wild-type p53 protein levels in H295R cells. Additionally, inhibition of PLK-1 restored wild-type p53’s transactivation and apoptotic functions in H295R cells, while these functions of mutant p53 were restored only to a smaller extent. Furthermore, inhibition of MDM2 with nutlin-3 reduced the viability of both the ACC cells and also reactivated wild-type p53′s apoptotic function. Inhibition of PLK-1 sensitized the ACC cell lines to MDM2 inhibition and this dual inhibition resulted in an additive apoptotic response in H295R cells with wild-type p53.
These preclinical studies suggest that targeting p53 through PLK-1 is an attractive chemotherapy strategy warranting further investigation in adrenocortical cancer.
KeywordsAdrenocortical carcinoma PLK-1 p53 Targeted therapy
Adrenocortical carcinoma (ACC) is a rare and often fatal cancer. Recent studies have shown that the outcome for patients with ACC has remained essentially unchanged in the past 25 years, with the overall 5-year survival of patients undergoing surgical resection being approximately 40 % [1–3]. Patients who present clinically with large, locally invasive tumors resulting in involved surgical margins or those who present with metastatic disease fare considerably worse with 5 year survival rates of 10–20 % [1–3], largely due to the limited effectiveness of chemotherapy. The only realistic opportunity for cure is a complete surgical resection, but unfortunately metastatic spread is already present in 40-70 % of patients at the time of diagnosis precluding cure [2–8]. Standard chemotherapy remains based on mitotane (Bristol-Myers Squibb Company, New York, New York) which was first approved in 1960. Mitotane, also known as o,p’-DDD, is a derivative of the pesticide DDT and an adrenolytic [7, 9–11]. The response rates to mitotane as a single agent is a relatively poor 23 %, but survival for those patients whose tumors do respond is improved from 14 to 50 months [7, 9, 10, 12, 13]. For most patients, mitotane is poorly tolerated due to its severe toxic side effects, including the obliteration of the healthy contralateral adrenal gland. Although in the original phase II trial, etoposide, doxorubicin, and cisplatin in combination with mitotane (EDP-M), was reported to produce clinical response rates up to 49 % of patients in advanced ACC patients , the results were not substantiated in the phase III trial comparing this regimen to streptozocin and mitotane. In this trial, the response rate to EDP-M was 23.2 % and the median progression-free survival interval was 5 months . Unfortunately, there is no approved second-line regimen for those whose disease progress on these agents.
Increasing, new treatments for cancer are being developed based on the analysis of genomic aberrations identified in tumor samples from patients. An improved understanding of the molecular oncogenesis of adrenocortical cancer (ACC) may elucidate novel therapeutic targets. The increased incidence of ACC in patients with Li-Fraumeni syndrome suggests the p53 pathway is involved in ACC progression [5, 6, 16]. In adults, however, mutation in p53 is seen in less than 25 % of cases suggesting that other elements of the p53 pathway may be perturbed [17–20]. Additionally, we and others have found that p53 is a major driver of differential gene expression when comparing ACC to normal adrenal glands or when comparing low and high-grade tumors [21, 22]. In the present analysis of gene expression profiles of ACC tumor samples, we found overexpression of polo-like kinase 1 (PLK-1), which is known to negatively regulate p53 activity, in 29 % of the tumors in our cohort and in 67 % of the tumors from the cohort published by Giordano, et al. . It has also been shown to interact with the human murine double minute 2 (MDM2) and control its activity . Therefore, we sought to delineate the role of PLK-1 in the modulation of the p53 pathway in ACC. We examined the effect of pharmacologic inhibition of PLK-1 on p53 function.
Gene expression data
We used previously published data sets from Affymetrix U133 Plus 2 chips that included both normal adrenal and ACC samples annotated with survival data [22, 23] to identify the number of ACC samples over-expressing PLK1. The.CEL files from Affymetrix U133 Plus 2 chips were downloaded from GEO (GSE10297 and GSE19750). The data were filtered to include only normal adrenal samples without evidence of disease in the contralateral gland and ACC tumor sample from patients over 18 years of age. Using the Expression File Creator in GenePattern , the data were normalized by gcRMA  with quantile normalization and background subtraction. Batch effects were minimized using COMBAT  with the non-parametric option, floored at 0.00001, and log2 transformed. Normalized expression data was extracted for the PLK1 probe set (202240_at), and the relative fold change to the geometric mean of the corresponding normal samples for each study was computed. The total data set encompassed 7 normal adrenal glands and 75 ACC. Of the ACC, 43 had usable survival information.
We validated the survival trend observed with array-based gene expression data using XENA  to pull out the mean normalized RSEM normalized count PLK1 expression for the gene and survival data from the TCGA ACC cohort. We used the built in Kaplan–Meier plotting function to determine the expression level cut-offs for a 2 group comparison for consistency, since there is no normal adrenal data in the TCGA data set.
To determine how SW-13 and H295R compared to tumors for PLK1 data, we mined GEO for PLK1 and beta-actin expression in SW-13 and H295 (the parental line of H295R) as well as all available ACC expression data sets. We downloaded the data and extracted the expression values for the corresponding probes to PLK1 and beta-actin, converted all data to log10, and plotted the results of PLK1 expression relative to beta-actin expression.
Eukaryotic cell culture
SW-13 and H295R cell lines were both purchased from ATCC (Manassas, VA). SW-13 cells were cultured in DMEM media with 10 % Fetal Bovine Serum (FBS), 1 % Penicillin–Streptomycin and 1 % l-Glutamine (all from Gibco, Grand Island, NY). H295R cells were cultured in DMEM/F12 media with 1 % Penicillin–Streptomycin, 1 % l-Glutamine (all from Gibco, Grand Island, NY), 2.5 % NuSerum and 1 % insulin-transferrin-selenium (ITS) (both from BD Biosciences, San Jose, CA). All cell cultures were maintained in a 5 % CO2 atmosphere at 37 °C.
In vitro drug dose–response curves
Sensitivity to BI-2536 (Tocris, Minneapolis, MN, USA), mitotane (Tocris, Minneapolis, MN, USA) and nutlin-3 (Tocris, Minneapolis, MN, USA) was tested in the following manner. H295R cells were plated at a density of 1750 cells/well in 40 µL of medium and SW-13 was plated at 1250 cells/wells in 40 µL DMEM with 2 % FBS. For dose response curves with BI-2536 alone, twenty-four hours after plating, threefold serial dilutions of BI-2536 in 10 μL of medium were added to the plates, with the final concentration at the highest dose being 100 µM. Cells were then incubated for an additional 72, 96, or 120 h at 37 °C in a humidified incubator. Viability was assessed by CellTiter Glo (Promega, Madison, WI, USA) and converted to normalized percent viability after normalizing to cells alone and with drug carrier. Double compound studies were conducted as above except IC25 concentrations (0.00684 µM for SW-13 and 0.0374 µM for H295R) of BI-2536 were kept constant and mitotane or nutlin-3 was evaluated in serial dilution. In those cases, normalized viability also included normalization to the median viability of BI-2536 alone.
Dose response curves and IC50 values for cell survival in the presence of the drugs were calculated using Prism5 software (GraphPad) using the log(inhibitor) vs. response—4 parameter function which fits the following equation: Y = Bottom + (Top–Bottom)/[1 + 10(X-LogIC50)] where X is the logarithm of concentration and Y is the percent cell survival. Y starts at the top and goes to bottom with a sigmoid shape as X increases. All experiments were repeated at least three times with a minimum of five replicates per dose per experiment and values are represented as averages with standard error.
In vitro caspase 3/7 induction assays
Induction of apoptosis after treatment with BI-2536 and nutlin-3 alone or together in combination was determined using the Caspase 3/7 Glo assay (Promega, Madison, WI). H295R cells were plated at a density of 1750 cells/well in 40 µl of medium and SW-13 was plated at 1250 cells/wells in 40 µl DMEM with 2 % FBS. 24 h after plating, the cells were treated with 100 µM, 33.3 µM, 11.1 µM, 3.703 µM and 1.234 µM of BI-2536 and nutlin-3 in a 10 µl volume. Induction of apoptosis was determined by the cleavage of caspase 3/7 at 8, 16, 24 and 48 h after compound addition. 5 µM Doxorubicin (Tocris, Minneapolis, MN, USA) was used as a positive control for induction of apoptosis. Percent caspase 3/7 activity was normalized to cells and to DMSO control. Induction of apoptosis with double compounds was determined as above except IC25 concentrations (0.00684 µM for SW-13 and 0.0374 µM for H295R) of BI-2536 were kept constant and nutlin-3 was evaluated in serial dilution. In those cases, percent caspase 3/7 activity was also normalization to the median caspase 3/7 activity of BI-2536 alone.
siRNA knockdown of PLK-1
Using 6 well plates, 2 × 105 SW-13 and 3.5 × 105 H295R cells were plated in their respective media without antibiotics and allowed to attach overnight. The next day, for SW-13 Lipofectamine2000 reagent (Invitrogen, Carlsbad, CA, USA) and for H295R TransIT-siQUEST reagent (Mirus Bio, Madison, WI, USA) was used to transfect in 20 nM PLK-1 siRNA (Qiagen, Valencia, CA, USA), an all-stars negative siRNA (Qiagen, Valencia, CA, USA) as a negative control, or a universally lethal positive-control siRNA directed against ubiquitin B (UBBs1)  (Qiagen, Valencia, CA, USA) using the manufacturer’s recommended protocols respectively. For transfection of SW-13 cells, 5 µl of Lipofectamine 2000 and 20 nM PLK-1, negative-control, or UBBs1 siRNA were mixed together in equal volumes, in serum free media (SFM) and allowed to incubate at room temperature for 30 min. All the media from the SW-13 wells was aspirated off and 500 µl of the siRNA—Lipofectamine 2000 mix was added to each well along with 1.5 ml of media without antibiotics. For transfection of H295R cells, 4 µl of TransIT-siQUEST reagent was diluted in SFM. 20 nM PLK-1, negative-control or UBBs1 siRNA were added to the diluted transfection reagent and allowed to incubate at room temperature for 20 min. 250 µl of the siRNA—TransIT-siQUEST mix was added to each well containing 1.25 ml of media without antibiotics. PLK-1 protein knockdown was confirmed by immunoblot 72 h after transfection.
To determine cell viability after PLK-1 transfection, SW-13 cells were reverse transfected with siRNA to PLK-1 or control siRNA and assayed for viability after 96 h. Briefly, 384 well plates were printed with 20 nM of Hs_PLK-1_7 siRNA, UBBs1, or negative control siRNAs that included a non-silencing scrambled siRNA and a siRNA directed against green fluorescent protein (GFP). A total of 20 µl of diluted Lipofectamine2000 solution was added to each well. After 30 min, 1200 cells for SW-13 in 20 µl of medium were added per well and then cultured at 37 °C. After 96 h, viability was assessed by CellTiter Glo following the manufacturer’s protocol. Relative luminescence values were normalized to cells and to cells with transfection agent to get normalized percent viability. To determine viability of H295R cells after PLK-1 transfection, H295R were transfected with PLK-1, negative-control or UBBs1 siRNA and assayed for viability after 72 h. Briefly, 20,000 H295R cells were plated in 80 µl in 96 well plates and allowed to attach overnight. The next day 20 µl of TransIT-siQUEST reagent and 20 nM PLK-1, negative-control or UBBs1 siRNA in SFM were added to each well containing 80 µl of media without antibiotics. Cells were assayed for viability using CellTitre Glo 72 h after transfection as per the manufacturer’s protocol. Relative luminescence values were normalized to cells alone and then cells with transfection agent alone to get normalized percent viability.
Total RNA extraction
6 × 105 SW-13 and 7.5 × 105 H295R cells were plated in 10 cm2 dishes in 10 ml of media. Cells were allowed to adhere for 24 h and were then treated with their respective BI-2536 IC10, IC25 and IC50 doses including DMSO controls. Total RNA was extracted 24 h later using the mirVana miRNA Isolation Kit (Ambion, Inc, Grand Island, NY, USA) as per the manufacturer’s protocol for total RNA extraction. This kit efficiently extracts RNAs larger than 10 nucleotides with specific protocols for either total RNA extraction or small RNA extraction. This allows us to use the kit for all experiments, reducing variability due to differences between kits.
RT-qPCR validation of p53 and p21 mRNA levels
Total RNA was reverse transcribed utilizing both random hexamer and oligo-dT primers and the RT2 First Strand cDNA Synthesis Kit (SABiosciences, Valencia, CA, USA). The resulting cDNA was amplified on the iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories, Inc, Hercules, CA, USA) using primer sets for TP53 (p53), CDKN1A (p21) and ACTB (β-actin) and RT2 SYBR Green Master Mix (all from SABiosciences, Valencia, CA, USA) and run according to manufacturer’s instructions. Melting curve analysis was performed to evaluate primer set specificity. Fold difference with respect to the vehicle control, DMSO, and relative to β-actin, which was used as the reference gene, was calculated using the Pfaffl method taking into account reaction efficiencies .
Western blot analysis
BI-2536 inhibitory concentrations
The blots were processed as described above for the detection of β-Actin (AbCam, Cambridge, MA, USA) in 5 % blocking solution which was used as an internal loading control. The β-Actin antibody was used at a dilution of 1:1000 along with the anti-rabbit secondary antibody also at a dilution of 1:1000. The actin membranes were also detected using the SuperSignal West Femto Chemiluminescent Substrate (Pierce, Thermo Scientific, Pittsburgh, PA, USA) and were visualized and quantitated with the Bio Spectrum 500 Imaging System (UVP, Cambridge, UK) and relative amounts of PLK-1, MDM2 and p53 protein are reported relative to β-Actin. All experiments were done three individual times and are represented as averages with standard error.
To determine PLK-1 protein expression after siRNA knockdown, blots for PLK-1 and β-Actin were processed as described above. Relative amounts of the PLK-1 protein after siRNA knockdown are reported relative to β-Actin. All experiments were done three individual times and are represented as means with standard error.
In vivo sensitivity assays
All statistical analyses were done with the Prism6 software (GraphPad) and included Analysis of Variance (ANOVA) with Tukey’s Multiple Comparison Test, Two-Way ANOVA with Dunnett’s multiple comparison test, and Survival using the log-rank method as implemented by the software. Cox Proportional Hazards were computed in R using the Survival package with stratification of samples by residual tumor status. P-values below 0.05 were considered strong a strong indication of non-random results, but where we report a trend, a p value is also reported even if it was above 0.05 to allow the reader to judge the non-random nature of the trend.
Evaluation of p53 and MDM2 genotypes
Studies of p53 mutations, p53 codon 72 polymorphism, and MDM2 SNP309 polymorphism are detailed in the Additional file 1, as the results of the studies were largely negative.
Inhibition of Polo-like kinase 1 (PLK-1) reduced the viability of ACC cell lines
IC50 values of BI-2536 and nutlin-3 alone and in combination
Nutlin-3 + BI-2536
IC50 values mitotane alone and in combination with BI-2536
Mitotane + BI-2536
Inhibition of PLK-1 reduced levels of mutant p53 protein but not wild type p53
Inhibition of PLK-1 restores functioning of wild type p53
Synergy of PLK-1 inhibition by BI-2536 with MDM2 inhibition by nutlin-3
Inhibition of PLK-1 and MDM2 should result in the reactivation of p53’s apoptotic function, due to dual relief of p53 inhibition . However, combined inhibition of PLK-1 and MDM2 did not increase apoptotic response of SW-13 over that seen with BI-2536 alone, whereas an additive apoptotic response was observed in H295R cells with wild-type p53, which is responsive to MDM2 inhibition (Fig. 7c, d).
Adrenocortical cancer remains a difficult malignancy to treat. New therapeutic regimens have not been forthcoming in part due to the relative rarity of the disease. Recently, the two major phase III studies, the FIRM-ACT trial and the OSI-906 study have been completed. The FIRM-ACT study was designed to establish a first-line chemotherapy standard which at this point is generally accepted by the ACC community as the combination of EDP-M . The OSI-906 study was done to investigate the efficacy of a small molecule IGF1R inhibitor in patients whose tumors have progressed on multiple drug chemotherapy. Alas, the results did not show improvement in progressive free survival in the treatment arm, although a small number of patients did appear to derive benefit . Clearly, a need still exists for further study and better treatments. The advent of rapid and high throughput methods for genomic analysis offers the potential ability to accelerate the process of identifying therapeutic leads. Candidate agents must still undergo traditional preclinical evaluation and those agents that are promising should then be entered into clinical trials to evaluate their efficacy in ACC.
Our studies on p53 in adrenocortical cancer are, in general, consistent with the findings of others. We found that p53 mutations in adult sporadic ACC are relatively uncommon. Others have previously reported mutation rates of 10–27 % [18–20, 35–37]. The increased incidence of ACC in children who have Li-Fraumeni syndrome, characterized by an inactivating mutation of p53 , however, suggests that one should examine the p53 pathway further in adults with ACC. Analysis of our expression array ACC data confirms that there is perturbation of the p53 pathway in many ACC cases, leading to the conclusion that there are mechanisms other than p53 mutation involved .
Targeting of other modifiers of p53 activity is a viable approach. One candidate therapeutic compound targeting polo-like kinase 1 (PLK-1) is advanced in this study. Polo-like kinases are a group of highly conserved serine-threonine kinases that regulate cell cycle checkpoints and cell division [39, 40]. PLK-1 is the most extensively studied, and it controls cell passage through M phase of the mitotic cycle . PLK-1 mRNA is over-expressed in most human cancers including those of the breast, lung, stomach, colon and rectum, ovary, pancreas and prostate . Over-expression of PLK-1 in cancers is thought to portend an adverse prognosis [43, 44]. Our analysis of PLK1 expression relative to survival in our expression data  combined with that of Giordano et al.  confirms this relationship in ACC. In vitro and in vivo experiments have suggested PLK-1 plays a role in carcinogenesis [40, 45]. Inhibition of PLK-1 in vitro leads to cell cycle arrest at G2/M and apoptosis in human cancer cell lines [39, 41]. Several PLK-1 inhibitors are under clinical development including BI-2536, which was investigated in phase II trials [30, 46] with mixed results. Another PLK-1 inhibitor, BI 6727 or volasertib in combination with low-dose cytarabine is being studied in a phase III trial in patients with acute myeloid leukemia, after encouraging results in a phase II trial . Our study offers evidence that BI-2536 may act to decrease levels of mutant p53 while not affecting wild type p53. It has been previously reported that BI-2536 has activity at nanomolar levels (IC50 range 0.002–0.025 µM) in cells lines that have either wild type or mutant p53 [30, 33]. It may be that patients with tumors harboring mutant p53 will respond to inhibition of PLK-1 by BI-2536 better than patients whose tumors harbor a wild-type p53. The results from our xenograft model are supportive of this. One attractive hypothesis that warrants investigation is that if one could inhibit mutant p53 and allow cancer cells to undergo apoptosis, one could enhance tumor response to treatment with other chemotherapeutic agents. In this way, a PLK-1 antagonist such as BI-2536 could be used as part of a combination chemotherapeutic strategy to treat ACC.
The mechanism by which BI-2536 affects mutant p53 levels is unclear and should be studied further. Several explanations are possible. PLK-1 may act to stabilize mutant p53 and protect it from degradation or inactivation. Inhibition of PLK-1 may act at the transcription or translation level. Alternatively, BI-2536 may have a direct effect on p53 independent of its effect on PLK-1. Lastly, we cannot assess based on the current experiments whether the effects seen are particular to ACC or whether other tumor types would behave similarly.
We also considered MDM2, a major negative regulator of p53, which was over-expressed at the RNA level in our samples. A single nucleotide polymorphism (SNP) at position 309 with a conversion of T to G generates a strong SP1 binding site and increases MDM2 expression [48, 49]. We did not observe a change in allele frequency from the expected population frequency in our ACC population, nor did we observe a significant increase MDM2 expression in tumors with a G allele compared to tumors homozygous for the T allele. Furthermore, ACC cell lines were relatively insensitive to pharmacological inhibition of MDM2. MDM2, therefore, seems unlikely to be the sole p53 regulator responsible for the disruption of p53 function in ACC. MDM2 remains of interest because agents targeting it, such as nutlins and in particular nutlin-3, are being investigated as anti-cancer drugs. These agents inhibit the interaction of MDM2 and p53 thereby stabilizing p53 leading to cellular senescence . As such nutlin-3 may work best in tumors with a normal or wild-type p53 gene, therefore making it potentially useful in the adult ACC patient population as approximately 75 % of tumors harbor wild-type p53.
We conclude from these preclinical studies that targeting p53 through PLK-1 is an attractive chemotherapy strategy warranting further investigation in adrenocortical cancer.
KJB, AB, and MJD conceived of and planned experiments. KJB oversaw the execution of experiments. AB, CL, MW and ER performed the all molecular biology work. AB, CL, and ED performed in vitro drug response assays. PG generated the xenograft data. KJB, AB, and CL analyzed the data. KJB, AB, and MJD wrote the manuscript. All authors read and approved the final manuscript.
We would like to thank Jung-Han Kim, Kathleen E. DelGiorno, Kaiti Schwartz, Michael T. Barrett and Daniel Von Hoff for their valuable contributions to this manuscript. This work was supported by the Advancing Treatments for Adrenocortical Carcinoma Fund and Kirsten’s Legacy from the Pasquinelli Family Foundation.
The studies reported in this manuscript support patent US9198910 “Methods for the Treatment of Cancer” on which KJB, MJD, and AB are inventors. MJD is a paid consultant for Tekmira Pharmaceuticals which is developing a PLK-1 inhibitor.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113(11):3130–3136. doi:10.1002/cncr.23886 PubMedView ArticleGoogle Scholar
- Fassnacht M, Allolio B (2009) Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23(2):273–289. doi:10.1016/j.beem.2008.10.008 PubMedView ArticleGoogle Scholar
- Roman S (2006) Adrenocortical carcinoma. Curr Opin Oncol 18(1):36–42 (00001622-200601000-00007 [pii]) PubMedView ArticleGoogle Scholar
- Allolio B, Fassnacht M (2006) Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91(6):2027–2037. doi:10.1210/jc.2005-2639 PubMedView ArticleGoogle Scholar
- Fassnacht M, Kroiss M, Allolio B (2013) Update in adrenocortical carcinoma. J Clin Endocrinol Metab. doi:10.1210/jc.2013-3020 Google Scholar
- Fassnacht M, Libe R, Kroiss M, Allolio B (2011) Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 7(6):323–335. doi:10.1038/nrendo.2010.235 PubMedView ArticleGoogle Scholar
- Tacon LJ, Prichard RS, Soon PS, Robinson BG, Clifton-Bligh RJ, Sidhu SB (2011) Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist 16(1):36–48. doi:10.1634/theoncologist.2010-0270 PubMedPubMed CentralView ArticleGoogle Scholar
- Zini L, Porpiglia F, Fassnacht M (2011) Contemporary management of adrenocortical carcinoma. Eur Urol 60(5):1055–1065. doi:10.1016/j.eururo.2011.07.062 PubMedView ArticleGoogle Scholar
- Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F et al (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15(4):1043–1053. doi:10.1677/ERC-08-0103 PubMedView ArticleGoogle Scholar
- Netto AD, Wajchenberg BL, Ravaglia C, Pereira VG, Shnaider J, Pupo AA et al (1963) Treatment of Adrenocortical Cancer with O,P’-Ddd. Ann Intern Med 59:74–78PubMedView ArticleGoogle Scholar
- Bapat AA, Demeure MJ, Bussey KJ (2012) A fly in the ointment: reassessing mitotane’s role in the treatment of adrenocortical carcinoma. Pharmacogenomics 13(11):1207–1209. doi:10.2217/pgs.12.90 PubMedView ArticleGoogle Scholar
- Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK et al (1991) Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6):1006–1013PubMedGoogle Scholar
- Costa R, Wesolowski R, Raghavan D (2011) Chemotherapy for advanced adrenal cancer: improvement from a molecular approach? BJU Int 108(10):1546–1554. doi:10.1111/j.1464-410X.2011.10464.x PubMedView ArticleGoogle Scholar
- Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12(3):657–666. doi:10.1677/erc.1.01025 PubMedView ArticleGoogle Scholar
- Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. doi:10.1056/NEJMoa1200966 PubMedGoogle Scholar
- Wandoloski M, Bussey KJ, Demeure MJ (2009) Adrenocortical cancer. Surg Clin North Am 89(5):1255–1267. doi:10.1016/j.suc.2009.06.019 PubMedView ArticleGoogle Scholar
- Hamid T, Kakar SS (2004) PTTG/securin activates expression of p53 and modulates its function. Mol Cancer. 3:18. doi:10.1186/1476-4598-3-18 PubMedPubMed CentralView ArticleGoogle Scholar
- Libe R, Groussin L, Tissier F, Elie C, Rene-Corail F, Fratticci A et al (2007) Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 13(3):844–850. doi:10.1158/1078-0432.CCR-06-2085 PubMedView ArticleGoogle Scholar
- Ohgaki H, Kleihues P, Heitz PU (1993) p53 mutations in sporadic adrenocortical tumors. Int J Cancer 54(3):408–410PubMedView ArticleGoogle Scholar
- Waldmann J, Patsalis N, Fendrich V, Langer P, Saeger W, Chaloupka B et al (2012) Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch Surg. 397(2):209–216. doi:10.1007/s00423-011-0868-6 PubMedView ArticleGoogle Scholar
- de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F et al (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27(7):1108–1115. doi:10.1200/JCO.2008.18.5678 PubMedView ArticleGoogle Scholar
- Demeure MJ, Coan KE, Grant CS, Komorowski RA, Stephan E, Sinari S et al (2013) PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery. 154(6):1405–1416. doi:10.1016/j.surg.2013.06.058 (discussion 16) PubMedPubMed CentralView ArticleGoogle Scholar
- Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J et al (2009) Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15(2):668–676. doi:10.1158/1078-0432.CCR-08-1067 PubMedPubMed CentralView ArticleGoogle Scholar
- Dias SS, Hogan C, Ochocka AM, Meek DW (2009) Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover. FEBS Lett 583(22):3543–3548. doi:10.1016/j.febslet.2009.09.057 PubMedView ArticleGoogle Scholar
- Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Genet 38(5):500–501. doi:10.1038/ng0506-500 PubMedView ArticleGoogle Scholar
- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4(2):249–264 (10.1093/biostatistics/4.2.249 4/2/249) PubMedView ArticleGoogle Scholar
- Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 8(1):118–127. doi:10.1093/biostatistics/kxj037 PubMedView ArticleGoogle Scholar
- Harradine KA, Kassner M, Chow D, Aziz M, Von Hoff DD, Baker JB et al (2011) Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin. Mol Cancer Res 9(2):173–182. doi:10.1158/1541-7786.MCR-10-0412 PubMedView ArticleGoogle Scholar
- Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45PubMedPubMed CentralView ArticleGoogle Scholar
- Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M et al (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17(4):316–322. doi:10.1016/j.cub.2006.12.037 PubMedView ArticleGoogle Scholar
- Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R et al (2012) Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol 19(1):e28–e35 (10.3747/co.19.866 conc-19-e28 [pii]) PubMedPubMed CentralView ArticleGoogle Scholar
- Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al (2004) Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279(24):25549–25561 (10.1074/jbc.M314182200 M314182200 [pii]) PubMedView ArticleGoogle Scholar
- Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223–241. doi:10.1146/annurev.pharmtox.48.113006.094723 PubMedPubMed CentralView ArticleGoogle Scholar
- Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H et al (2015) Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 16(4):426–435. doi:10.1016/S1470-2045(15)70081-1 PubMedView ArticleGoogle Scholar
- Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N et al (2012) TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 97(3):E476–E485. doi:10.1210/jc.2011-1982 PubMedView ArticleGoogle Scholar
- Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM et al (1994) p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 78(3):790–794PubMedGoogle Scholar
- Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O et al (2014) Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 46(6):607–612. doi:10.1038/ng.2953 PubMedView ArticleGoogle Scholar
- Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ et al (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256. doi:10.1200/JCO.2008.16.6959 PubMedView ArticleGoogle Scholar
- Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD (2006) A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 12(17):5182–5189. doi:10.1158/1078-0432.CCR-06-0214 PubMedView ArticleGoogle Scholar
- Santamaria A, Neef R, Eberspacher U, Eis K, Husemann M, Mumberg D et al (2007) Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 18(10):4024–4036. doi:10.1091/mbc.E07-05-0517 PubMedPubMed CentralView ArticleGoogle Scholar
- Barr FA, Sillje HH, Nigg EA (2004) Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5(6):429–440. doi:10.1038/nrm1401 PubMedView ArticleGoogle Scholar
- Schoffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 14(6):559–570. doi:10.1634/theoncologist.2009-0010 PubMedView ArticleGoogle Scholar
- Eckerdt F, Yuan J, Strebhardt K (2005) Polo-like kinases and oncogenesis. Oncogene 24(2):267–276. doi:10.1038/sj.onc.1208273 PubMedView ArticleGoogle Scholar
- Weichert W, Ullrich A, Schmidt M, Gekeler V, Noske A, Niesporek S et al (2006) Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci 97(4):271–276. doi:10.1111/j.1349-7006.2006.00170.x PubMedView ArticleGoogle Scholar
- Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H et al (1994) Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 91(5):1736–1740PubMedPubMed CentralView ArticleGoogle Scholar
- Muller-Tidow C, Bug G, Lubbert M, Kramer A, Krauter J, Valent P et al (2013) A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol 163(2):214–222. doi:10.1111/bjh.12518 PubMedGoogle Scholar
- Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. vol 9. 2014Google Scholar
- Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5):591–602. doi:10.1016/j.cell.2004.11.022 PubMedView ArticleGoogle Scholar
- Knappskog S, Lonning PE (2011) Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription. 2(5):207–210 (16813 [pii]) PubMedPubMed CentralView ArticleGoogle Scholar